Semaglutide: what the evidence shows

What semaglutide is

Semaglutide is a GLP-1 receptor agonist. It is built to resemble a hormone the gut releases after eating, called glucagon-like peptide-1, and it activates the same receptor that hormone does. That receptor sits in the pancreas, the brain and the gut, and activating it slows stomach emptying, increases the feeling of fullness and affects how the pancreas releases insulin.

That is a real, well-characterized mechanism, not a marketing description. It is also not unique to semaglutide. Several approved drugs work the same way. What sets semaglutide apart is a specific engineering choice: a fatty acid chain that lets it bind albumin in the blood. That is what gives it a long enough duration to be dosed weekly rather than daily.

None of that is dosing information. It describes what the molecule does and why it is given on the schedule it is given, not how to give it.

One molecule, three approved products, and a fourth thing entirely

This is the fact most often lost in how semaglutide is discussed. It is also the same rule this site applies to PT-141: approval attaches to a specific product for a specific indication in a specific population, not to a chemical formula.

Semaglutide is the active ingredient in three separate FDA-approved products. Ozempic, an injection, was approved first, to improve blood sugar control in adults with type 2 diabetes, with its label stating initial U.S. approval in 2017. Rybelsus is an oral tablet form of the same molecule, also approved for type 2 diabetes. Wegovy is a higher-dose injection approved specifically for chronic weight management. FDA cleared it on June 4, 2021, for adults with obesity, or with overweight plus at least one weight-related condition such as hypertension or type 2 diabetes.

Each of those went through its own review of safety and effectiveness for its own indication. A telehealth peptide provider marketing 'semaglutide' for weight loss is, when selling the approved product, selling the Wegovy formulation and indication, whatever the invoice calls it.

A fourth category exists alongside all three, and it is not an approved product at all: a compounded copy of semaglutide, prepared by a pharmacy rather than manufactured by the drug's sponsor. That category is common in this market, it is not automatically illegitimate, and it is not what the rest of this article is about. Its own regulatory history, including when it was permitted and when that permission ended, is covered in full in the companion article on compounded GLP-1s.

The trial evidence behind the weight-management approval

Wegovy's approval rested on the STEP program, a set of phase 3 randomized, double-blind, placebo-controlled trials. The lead trial, STEP 1, enrolled adults with obesity or overweight plus a weight-related condition, none of whom had diabetes, and followed them for 68 weeks.

Published in the New England Journal of Medicine in 2021, STEP 1 reported that participants assigned to semaglutide lost an average of 14.9% of body weight, compared with 2.4% on placebo. FDA's own review, drawing on this and the other STEP trials, found a statistically significant reduction in body weight compared with placebo across the program.

That trial was funded by Novo Nordisk, the company that also markets the drug. Company funding does not make a randomized, blinded, FDA-reviewed trial worthless, and it is also not nothing. Both things are true at once, and a reader is better served knowing the sponsor than not.

This is where semaglutide sits apart from almost everything else covered on this site. The bar for strong evidence, as this site defines it, is an approved indication with randomized controlled trial data behind it. That bar was cleared here, by a regulator with subpoena power and full access to the underlying data, not by a citation count.

What the label discloses, plainly

The Wegovy label carries a boxed warning, FDA's strongest label warning category, for thyroid C-cell tumors. It states that semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures, and that whether it causes the same tumors in humans, including medullary thyroid carcinoma, has not been determined. The drug is contraindicated in anyone with a personal or family history of that cancer or of Multiple Endocrine Neoplasia syndrome type 2.

The label also lists several further warnings: acute pancreatitis, acute gallbladder disease, and hypoglycemia in combination with certain other diabetes medications. It adds acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and suicidal behavior or ideation. The most common adverse reactions, reported in five percent or more of patients, are gastrointestinal: nausea, diarrhea, vomiting, constipation and related symptoms.

Disclosing what a label says is not medical advice and is not a recommendation. It is the plain content of a public document, and a reader deciding whether to trust a source that describes 'semaglutide' should be able to check it against what the approved product's own label says.

What the published literature looks like beyond the pivotal trials

A search of PubMed in September 2026 for semaglutide in a title or abstract returns 5,420 records. Run through the same randomized-controlled-trial filter in the same session, that narrows to 303. A positive control matters here as much as it does for a compound with no trials at all. Through the identical filter, aspirin returns 5,085 and a deliberately nonsense search term returns zero, which is how the filter is confirmed to be working rather than silently broken.

A registry search on ClinicalTrials.gov in the same session returns 748 studies naming semaglutide as an intervention, against 2,181 for aspirin and zero for a nonsense term. Registered and published are not the same thing, and a registered study that has not yet reported tells a reader a question is being asked, not that it has been answered. What the count establishes here is scale: semaglutide is one of the most extensively trialed compounds this site covers, in either direction.

That volume is also why a single grade needs a caveat. Trials exist for cardiovascular risk reduction, for a liver condition, and for other uses beyond the original two indications, each reviewed and approved on its own record. The grade discussed here covers the weight-management use, which is the one the peptide and telehealth market overwhelmingly sells.

What "strong evidence" does and does not mean here

Strong evidence means an approved indication with randomized controlled trial data behind it. It does not mean risk-free, and the boxed warning above is the plain proof of that. It also does not mean every seller offering semaglutide is offering the reviewed product, at the reviewed dose, in a form the trials actually tested.

The grade is a property of the compound as evaluated for this use. It travels with the molecule only as far as the approved product and its label go. A compounded version prepared outside that process has not been through the same review, whatever ingredient list it shares.

That distinction is the reason this site keeps the evidence grade and the sourcing question separate. A high grade here is not a verdict on any particular vial, and it was never meant to be read as one.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. NDA 215256 approval letter — Wegovy (semaglutide) injection — U.S. Food and Drug Administration, June 2021
2. Wegovy (semaglutide) injection — prescribing information — U.S. Food and Drug Administration, June 2021
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine, March 2021
4. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — U.S. Food and Drug Administration, April 2026
5. PubMed literature census for semaglutide, run with a positive control through the same filter — National Library of Medicine, September 2026
6. Registered study census for semaglutide, run with a positive control through the same query — ClinicalTrials.gov, National Library of Medicine, September 2026